Sign in
bf/NASDAQ:CYT_icon.jpeg

NASDAQ:CYT

Cyteir Therapeutics, Inc.

  • Stock

USD

Last Close

3.09

15/03 20:00

Market Cap

108.71M

Beta: -

Volume Today

1.01M

Avg: 56.88K

PE Ratio

−3.67

PFCF: −4.34

OverviewFinancialsFilingspeopleOwnershipAPIChartData
Income StatementBalance SheetCash FlowKey MetricsRatios
Excel Tearsheet
Quarterly
Yearly

Preview

Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page

Subscribe NowHelp
Dec '19
Dec '20
Dec '21
Dec '22
average inventory
630K
-
-19K
103.02%
-19K
0%
average payables
1.15M
-
1.74M
51.64%
1.46M
16.15%
average receivables
113.50K
-
50.50K
55.51%
19K
62.38%
book value per share
-1.46
-
-2.01
37.88%
9.61
577.75%
4.15
56.82%
capex per share
-0.01
-
-0.04
419.88%
-0.06
71.38%
-0.01
85.49%
capex to depreciation
-0.62
-
-2.42
291.47%
-2.48
2.50%
-0.47
81.18%
capex to operating cash flow
0.01
-
0.05
505.25%
0.03
28.03%
0.01
77.77%
capex to revenue
cash per share
1.49
-
0.46
69.33%
9.73
2,025.12%
4.17
57.13%
days of inventory on hand
days payables outstanding
days sales outstanding
debt to assets
0.01
-
debt to equity
0.01
-
dividend yield
earnings yield
-0.04
-
-0.05
12.59%
-0.19
275.00%
-0.76
302.02%
enterprise value
309.13M
-
404.75M
30.93%
31.98M
92.10%
-88.03M
375.23%
enterprise value over ebitda
-19.45
-
-19.66
1.03%
-0.76
96.15%
1.83
341.46%
ev to operating cash flow
-17.61
-
-21.83
24.00%
-0.89
95.93%
2.07
333.17%
ev to sales
free cash flow per share
-0.91
-
-0.81
10.84%
-1.91
135.20%
-1.21
36.37%
free cash flow yield
-0.05
-
-0.05
10.84%
-0.17
259.93%
-0.74
338.49%
graham net net
-1.54
-
-2.13
37.97%
9.32
538.23%
3.97
57.34%
graham number
5.04
-
6.28
24.60%
21.48
242.15%
10.78
49.81%
income quality
1.17
-
0.89
23.71%
0.86
3.93%
0.92
7.96%
intangibles to total assets
0
-
0
0
0
interest coverage
72.11
-
interest debt per share
0.01
-
inventory turnover
invested capital
0.01
-
market cap
338.14M
-
415.69M
22.93%
221.71M
46.67%
58.20M
73.75%
net current asset value
-29.27M
-
-49.63M
69.59%
184.98M
472.68%
142.26M
23.09%
net debt to ebitda
1.83
-
0.53
70.91%
4.49
745.20%
3.04
32.38%
net income per share
-0.77
-
-0.87
12.59%
-2.14
145.04%
-1.25
41.66%
operating cash flow per share
-0.90
-
-0.78
14.10%
-1.85
138.12%
-1.21
34.75%
payables turnover
receivables turnover
research and ddevelopement to revenue
return on tangible assets
-0.48
-
-1.52
216.12%
-0.21
85.94%
-0.29
34.57%
revenue per share
roe
0.53
-
0.43
18.34%
-0.22
151.29%
-0.30
35.12%
roic
0.57
-
0.44
23.28%
-0.22
151.16%
-0.31
39.17%
sales general and administrative to revenue
shareholders equity per share
-1.46
-
-2.01
37.88%
9.61
577.75%
4.15
56.82%
stock based compensation to revenue
tangible asset value
-28.34M
-
-48.03M
69.51%
187.29M
489.94%
146.29M
21.89%
tangible book value per share
-1.46
-
-2.01
37.88%
9.61
577.75%
4.15
56.82%
working capital
28.46M
-
8.99M
68.40%
185.57M
1,963.22%
143.89M
22.46%

All numbers in USD (except ratios and percentages)